33 results
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
8 Sep 20
Form 6K for May 2020
1:15pm
by the COVID-19 pandemic.
The Company is relying on exemptive relief recently granted by Canadian securities regulatory authorities that allows … to the coronavirus disease 2019 pandemic, securities regulatory authorities in Canada have granted a blanket exemption allowing issuers an additional 45 days
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
22 Apr 20
Replicel Postpones Filing of Annual Financial Statements and MD&A Due to COVID-19 Related Delays
1:56pm
December 31, 2019, due to logistics and delays caused by the COVID-19 pandemic.
Replicel is relying on exemptive relief recently granted by Canadian … Instrument 51-102 by April 29, 2020. In response to the coronavirus disease 2019 pandemic, securities regulatory authorities in Canada have granted a blanket
6-K
EX-99.4
REPCF
Replicel Life Sciences Inc.
8 Sep 20
Replicel Announces Extension to Private Placement
7:14pm
and analysis for the six-month period ended June 30, 2020 (the “Interim Documents”), due to logistics and delays caused by the COVID-19 pandemic … and 5.1(2) of National Instrument 51-102. In response to the coronavirus disease 2019 pandemic, securities regulatory authorities in Canada have granted
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
8 Sep 20
Form 6K for May 2020
1:15pm
for the three month period ended March 31, 2020, due to logistics and delays caused by the COVID-19 pandemic.
The Company is relying on exemptive relief … (2) of National Instrument 51-102 by June 1, 2020. In response to the coronavirus disease 2019 pandemic, securities regulatory authorities in Canada
6-K
EX-99.5
REPCF
Replicel Life Sciences Inc.
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
or inactions of governmental authorities or suppliers, epidemics, pandemics (including the COVID-19 pandemic), war, embargoes, severe weather, fire, earthquakes … , 2020, the World Health Organization declared a pandemic in connection with the outbreak of COVID-19, and as of the date of this Agreement, each Party
6-K
EX-99.5
3860n231gdk38te1v1n
8 Sep 20
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
1:17pm
6-K
EX-99.1
xik8k585t1q6
8 Sep 20
Replicel Life Sciences Inc. Announces Application for a Management Cease Trade Order
1:17pm
6-K
EX-99.1
w05wdd3s4
28 Jul 22
Current report (foreign)
2:52pm
6-K
EX-99.3
xxyk90h6 efr
3 Feb 21
RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement
12:03pm
6-K
EX-99.2
4id3d v9949xids1f86
31 Jul 20
Condensed Consolidated Interim Financial Statements
9:14pm
6-K
EX-99.2
fsayp
3 Aug 20
Consolidated Financial Statements
12:00am
6-K
EX-99.3
adze6bj30t k02fv2df
22 Dec 20
Current report (foreign)
3:05pm
6-K
EX-99.1
b6im326gal ilr
31 Jul 20
Condensed Consolidated Interim Financial Statements
9:14pm
6-K
EX-99.1
cl3dqlqeucp4b6suk
15 Oct 20
Condensed Consolidated Interim Financial Statements
5:15pm
6-K
EX-99.1
0u8rd4 bni
30 Nov 20
Condensed Consolidated Interim Financial Statements
5:19pm
6-K
EX-99.2
97v769qhd2hrsl
30 Nov 20
Condensed Consolidated Interim Financial Statements
5:19pm
6-K
EX-99.2
42tqq 7ugbzbl8q
6 Sep 22
Condensed Consolidated Interim Financial Statements
12:42pm